235. Hypoparathyroidism Clinical trials / Disease details
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000500-29-FR (EUCTR) | 03/06/2016 | 26/04/2016 | A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia | A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia - ACTICAS | Autosomal dominant hypocalcemia (ADH) MedDRA version: 19.0;Level: PT;Classification code 10021041;Term: Hypoparathyroidism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: FORSTEO-R Product Name: FORSTEO-R INN or Proposed INN: Tériparatide Other descriptive name: FORSTEO-R Trade Name: ESIDREX-R 25 mg Product Name: ESIDREX-R 25 mg INN or Proposed INN: Hydrochlorothiazide Other descriptive name: ESIDREX-R Trade Name: UN-ALPHA-R 0.25µg Product Name: UN-ALPHA-R 0.25µg INN or Proposed INN: Alfacalcidol Other descriptive name: UN-ALPHA-R | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 25 | Phase 2 | France |